BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 32876018)

  • 21. Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.
    van de Schootbrugge-Vandermeer HJ; Kooyker AI; Wisse PHA; Nagtegaal ID; Geuzinge HA; Toes-Zoutendijk E; de Jonge L; Breekveldt ECH; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Lansdorp-Vogelaar I; Spaander MCW; van Leerdam ME
    Endoscopy; 2023 Dec; 55(12):1061-1069. PubMed ID: 37793423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
    Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
    Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the FIT-based National Colorectal Cancer Screening Program in Slovenia.
    Tepeš B; Bracko M; Novak Mlakar D; Stefanovic M; Stabuc B; Frkovic Grazio S; Maucec Zakotnik J
    J Clin Gastroenterol; 2017 Jul; 51(6):e52-e59. PubMed ID: 27552327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colorectal Cancer Screening Pilot Project in Tehran-Iran, a Feasibility Study.
    Salimzadeh H; Sauvaget C; Delavari A; Sadeghi A; Amani M; Salimzadeh S; Karimi A; Ghanbari Motlagh A; Lucas E; Basu P; Malekzadeh R
    Arch Iran Med; 2023 Mar; 26(3):138-146. PubMed ID: 37543936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality indicators for screening colonoscopy and colonoscopist performance and the subsequent risk of interval colorectal cancer: a systematic review.
    Lund M; Trads M; Njor SH; Erichsen R; Andersen B
    JBI Database System Rev Implement Rep; 2019 Nov; 17(11):2265-2300. PubMed ID: 31188154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
    Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
    Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
    [No Abstract]   [Full Text] [Related]  

  • 31. Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program.
    Wisse PHA; de Boer SY; Oudkerk Pool M; Terhaar Sive Droste JS; Verveer C; Meijer GA; Dekker E; Spaander MCW
    Endoscopy; 2024 May; 56(5):364-372. PubMed ID: 38101446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data quality and colonoscopy performance indicators in the prevalent round of a FIT-based colorectal cancer screening program.
    Lund M; Erichsen R; Valori R; Møller Jensen T; Helle Njor S; Laurberg S; Andersen B;
    Scand J Gastroenterol; 2019 Apr; 54(4):471-477. PubMed ID: 30978128
    [No Abstract]   [Full Text] [Related]  

  • 33. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases.
    Siripongpreeda B; Mahidol C; Dusitanond N; Sriprayoon T; Muyphuag B; Sricharunrat T; Teerayatanakul N; Chaiwong W; Worasawate W; Sattayarungsee P; Sangthongdee J; Prarom J; Sornsamdang G; Soonklang K; Wittayasak K; Auewarakul CU
    BMC Gastroenterol; 2016 Aug; 16(1):101. PubMed ID: 27553627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
    Malagón M; Ramió-Pujol S; Serrano M; Amoedo J; Oliver L; Bahí A; Miquel-Cusachs JO; Ramirez M; Queralt-Moles X; Gilabert P; Saló J; Guardiola J; Piñol V; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil LJ
    PLoS One; 2020; 15(12):e0243158. PubMed ID: 33259546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.
    Ng SC; Ching JY; Chan V; Wong MC; Suen BY; Hirai HW; Lam TY; Lau JY; Ng SS; Wu JC; Chan FK; Sung JJ
    Aliment Pharmacol Ther; 2013 Oct; 38(7):835-41. PubMed ID: 23957462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.